חוב לטווח קצר להון Innate Pharma (IPHA)
The following quotes for Innate Pharma S.A. (IPHA) on GURU.Markets show the 0.00 indicator. Innate Pharma S.A. (IPHA) operates in the immunotherapy oncology sector. The business faces fierce competition and concerns regarding final drug trials. The French research center minimizes disruptions by utilizing third-party bio-manufacturing plants. The firm is currently developing a new type of antibodies, leveraging collaborations with the market's largest players.
פילוחים אנליטיים של חברת Innate Pharma S.A.
Investors assess fundamental risks through the analysis of liquidity and debt load. For Innate Pharma S.A. (IPHA), whose revenues depend on partner payments for antibody clinical trials, controlling current liabilities is critical. By analyzing the change in the ratio of short-term borrowed capital to equity, we determine the proportion of debt due within one year relative to equity. Low values confirm the financial stability of Innate Pharma S.A. (IPHA) during the period of awaiting test results.